This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Solubility: Soluble in DMSO at 200 mg/mL, soluble in ethanol at 25 mg/mL with slight warming. Ibrutinib, also known as PCI-32765, is a selective and irreversible inhibitor of the enzyme Bruton's tyrosine kinase (BTK). It inhibited BTK potently, with an IC50 of 0.72 nM in enzymology assays and with an IC50 of 10 nM in cellular assay with Ramos cells. It demonstrated preference toward BTK over closely related kinases, blocked B cell function and BTK-dependent processes, and demonstrated clear efficacy in a mouse arthritis model. Young P.R., et al. 'Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.' ChemMedChem. 2: 58-61 (2007). Ibrutinib blocked B-cell antigen receptor (BCR) signaling in human peripheral B cells at concentrations which did not change T cell receptor signaling, reduced the level of circulating autoantibodies and completely suppressed collagen-induced arthritis in mice, inhibited the production of autoantibodies and the development of kidney disease in the MRL-Fas(lpr) lupus model, and induced objective clinical responses in dogs with spontaneous B-cell non-Hodgkin lymphoma. Active site occupancy of BTK was closely correlated with the inhibition of BCR signaling and in vivo efficacy. Honigberg L.A., et al. 'The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.' Proc. Natl. Acad. Sci. USA 107: 13075-13080 (2010). Ibrutinib was well tolerated and had significant activity in patients with relapsed/refractory B-cell malignancies. Advani R.H., et al. 'Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.' J. Clin. Oncol. 31: 88-94 (2013).
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the usability of this website, serve for direct advertising or simplify interaction with other websites and social networks, will only be used with your consent.
More information